Jobs
-
Consort Medical has announced that its Bespak subsidiary has entered into a multi-year agreement to supply its proprietary integrated dose counter system and the valve for a commercial pMDI. This is the first commercial use… Read more . . .
-
Novartis Pharmaceuticals Canada has announced the launch of the Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI for the treatment of COPD in Quebec, the first province in Canada to reimburse the inhaler. The Régie de l’assurance maladie… Read more . . .
-
Mast Therapeutics has announced that the first patients have been dosed in two Phase 2a studies of AIR001 sodium nitrite inhalation solution for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).… Read more . . .
-
Vectura Chief Executive Chris Blackwell will step down from that position at the end of June 2015, the company has announced. Blackwell has been with the company since 2002. The company’s board says that it… Read more . . .
-
Afrezza inhaled insulin is now available by prescription in the US, Sanofi and Mannkind Corporation have announced. The FDA approved the insulin DPI for the treatment of type 1 and type 2 diabetes in June… Read more . . .
-
Evoke Pharma has announced that slower than expected enrollment in a Phase 3 clinical trial of its EVK-001 metoclopramide nasal spray for the treatment of diabetic gastroparesis in women will result in delayed completion of… Read more . . .
-
Theravance Biopharma and Mylan announced that they have entered into a development and commercialization agreement for TD-4208, a novel nebulized LAMA for the treatment of COPD and other respiratory diseases that is currently in Phase… Read more . . .
-
Adamis Pharmaceuticals has announced that the US and Japanese patent offices have approved applications for patents related to the Taper dry powder inhaler, an API-only device that was developed initially by 3M Drug Delivery Systems.… Read more . . .
-
A study published online in Pediatrics finds that children using a triamcinolone nasal spray for allergic rhinitis grew on average 0.44 cm/year less than children using a placebo nasal spray (5.65 cm/year compared to 6.09… Read more . . .
-
GlaxoSmithKline has announced that both the Arnuity Ellipta fluticasone furoate DPI and the Incruse Ellipta umeclidinium bromide DPI are now available in the US. Arnuity Ellipta was approved by the FDA in August 2014 for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK